Jennifer Hammond, PhD

Head of Antiviral Development
Pfizer Inc
Collegeville, PA, United States

Jennifer Hammond is a virologist with a PhD in Infectious Diseases and Microbiology from the University of Pittsburgh. She has over 20 years experience in anti-viral and anti-infective pharmaceutical development and has held various research, clinical and medical roles within the pharmaceutical industry. Jennifer led the team responsible for the conduct of Phase 2/3 clinical trials of PAXLOVID. She is currently Vice President, Head of Antiviral Development at Pfizer.

Disclosure(s): Pfizer, Inc: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 88 - Efficacy of nirmatrelvir-ritonavir in high-risk trial participants with prior SARS-CoV-2 infection or vaccination: a pooled analysis

  Thursday, October 17, 2024
  10:42 AM – 10:54 AM US PT

• 580 - Pharmacokinetics (PK) and Safety of Nirmatrelvir/Ritonavir (NMV/r) in Non-Hospitalized Symptomatic Pediatric Patients Ages 6 Years and Older with COVID-19 who are at Increased Risk of Progression to Severe Disease (EPIC-Peds)

  Saturday, October 19, 2024
  2:45 PM – 2:57 PM US PT